• InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment f... 12/22/2022
• InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904 11/10/2022
• InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Trea... 9/30/2022
• InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COV... 7/1/2022
• InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19 10/13/2021
• InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Indu... 7/22/2020
• InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part in COVID-19 6/18/2020
• InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed ... 4/1/2020
• InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference 2/20/2020
• InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shares 5/9/2018
• InflaRx announces appointment of Tony Gibney to its Board of Directors 2/7/2018
• InflaRx receives IND acceptance to proceed with a Phase IIb Trial 1/10/2018
• InflaRx to Present at Upcoming Investor Conferences 1/5/2018